Top 3 drug approvals in oncology: April 2021

Over the past month, several oncology drugs have been newly approved; in this piece we provide you with the key facts to keep you up-to-date with the industry news. Trodelvy® (sacituzumab govitecan) Approved: 7 April 2021 Company: Gilead Sciences, Inc. (CA, USA) Indication: Metastatic triple-negative breast cancer and urothelial cancer At the start of the month Gilead Sciences gained approval from the US FDA for Trodelvy® (sacituzumab govitecan) to treat patients with unresectable, locally advanced or metastatic triple-negative breast cancer. The patients must have been treated with two or more prior systemic therapies, including at least one for metastatic disease....